Bile Acid Sequestrants

Guyton, John R.; Goldberg, Anne C.

doi:10.1016/b978-141605469-6.50027-5

Cited by 5 publications

(2 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cholestyramine is an inexpensive, FDA-approved drug with few side effects (Beckett and Wilhite, 2015; Jacobson et al, 2007). Cholestyramine has been used clinically for over 50 years, including in hospital patient populations that would be targets for adjunctive cholestyramine therapy (Ballantyne, 2009). Cholestyramine does have potential to interfere with other orally administered drugs, which could be a risk considered on a patient by patient basis (Scaldaferri et al, 2013).…”

Section: Discussionmentioning

confidence: 99%

An adjunctive therapy administered with an antibiotic prevents enrichment of antibiotic-resistant clones of a colonizing opportunistic pathogen

Morley

Kinnear

Sim

et al. 2020

Preprint

View full text Add to dashboard Cite

Therapeutic antibiotic use drives the spread of antibiotic resistance, a major threat to public health. Ideally, clinicians could treat infections with antibiotics without fueling transmission of resistant pathogens. Here, we show proof of concept for an adjunctive therapy approach that allows treatment of target pathogens without the emergence and onward transmission of resistance. Like many of the bacterial species responsible for the antimicrobial resistance crisis, vancomycin-resistant Enterococcus (VRE) is a colonizing opportunistic pathogen and an important cause of drug-resistant healthcare-associated infections. VRE causes life-threatening infections in the bloodstream, but spreads via fecal-oral transmission because it asymptomatically colonizes the gastrointestinal (GI) tract. Thus, there is a physical separation between the VRE targeted by treatment (those in the blood) and the VRE contributing to onward transmission (those in the GI tract). An oral adjuvant that can bind or inactivate antibiotic in the GI tract would make possible intravenous patient treatment without promoting transmissible resistance. We tested this idea in a mouse model of VRE GI tract colonization using cholestyramine, which we show binds daptomycin, one of the few remaining front-line antibiotics against VRE. Adjunctive cholestyramine therapy reduced the fecal shedding of daptomycin-resistant VRE by up to 80-fold in mice treated with daptomycin. These results provide proof of concept for an approach that could reduce the spread of antibiotic resistance for many important hospital pathogens.

show abstract

Section: Discussionmentioning

confidence: 99%

An adjunctive therapy administered with an antibiotic prevents enrichment of antibiotic-resistant clones of a colonizing opportunistic pathogen

Morley

Kinnear

Sim

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Although interference of BAs with the EHC through treatment with cholesterol-lowering BA-binding resins or natural BAs has been used extensively in therapeutic intervention efforts, 11,12 the development of synthetic FXR agonists and antagonists as well as drugs influencing BA transporters 13 has led more recently to the availability of new classes of drugs. These drugs are under evaluation for clinical conditions such as nonalcoholic steatohepatitis and cholestatic liver disease, as well as metabolic diseases such as diabetes, hyperlipidemia, and insulin resistance.…”

mentioning

confidence: 99%

A Physiology-Based Model of Bile Acid Distribution and Metabolism Under Healthy and Pathologic Conditions in Human Beings

Voronova¹,

Соколов²,

Al-Khaifi

et al. 2020

Cellular and Molecular Gastroenterology and Hepatology

View full text Add to dashboard Cite

A physiological model capturing distribution and biotransformation of 3 major bile acids (cholic, chenodeoxycholic, and deoxycholic acids) was developed based on previous modeling works and used to simulate the effect of enterohepatic circulation perturbations on bile acid metabolism. BACKGROUND & AIMS:Disturbances of the enterohepatic circulation of bile acids (BAs) are seen in a number of clinically important conditions, including metabolic disorders, hepatic impairment, diarrhea, and gallstone disease. To facilitate the exploration of underlying pathogenic mechanisms, we developed a mathematical model built on quantitative physiological observations across different organs.

show abstract

The role of bile acid metabolism in bone and muscle: from analytics to mechanisms

Herrmann,

Rodriguez-Blanco,

Balasso

et al. 2024

Critical Reviews in Clinical Laboratory Sciences

View full text Add to dashboard Cite

Bile Acid Sequestrants

Cited by 5 publications

References 63 publications

An adjunctive therapy administered with an antibiotic prevents enrichment of antibiotic-resistant clones of a colonizing opportunistic pathogen

An adjunctive therapy administered with an antibiotic prevents enrichment of antibiotic-resistant clones of a colonizing opportunistic pathogen

A Physiology-Based Model of Bile Acid Distribution and Metabolism Under Healthy and Pathologic Conditions in Human Beings

The role of bile acid metabolism in bone and muscle: from analytics to mechanisms

Contact Info

Product

Resources

About